Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm, Residual × Letrozole × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 346 Polycystic Ovary Syndrome 38 Endometrial Neoplasms 22 Neoplasm Metastasis 19 Ovarian Neoplasms 16 Neoplasms 11 Infertility 11 Fallopian Tube Neoplasms 8 Advanced Breast Cancer 8 Carcinoma, Intraductal, Noninfiltrating 7 Carcinoma, Ductal, Breast 7 Breast Neoplasms, Male 7 Triple Negative Breast Neoplasms 6 Recurrence 6 Osteoporosis 6 Carcinoma, Lobular 6 Breast Diseases 6 Breast Carcinoma In Situ 6 Prostatic Neoplasms 4 Leiomyoma 4 Infertility, Female 4 Hereditary Sensory and Autonomic Neuropathies 4 Breast Cancer Metastatic 4 Neoplasms, Hormone-Dependent 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Non-Small-Cell Lung 3 Uterine Neoplasms 2 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumor 2

Interventions

Cyclophosphamide 22 blinatumomab 18 Cytarabine 15 fludarabine 13 Azacitidine 12 venetoclax 10 fludarabine phosphate 10 Rituximab 8 Lenalidomide 7 Dexamethasone 7 Methotrexate 6 Daunorubicin 6 Mercaptopurine 5 daratumumab 4 Whole-Body Irradiation 4 Vincristine 4 Melphalan 4 Idarubicin 4 Etoposide 4 Busulfan 4 pembrolizumab 3 obinutuzumab 3 Radiotherapy 3 Immunotherapy, Adoptive 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Drug Therapy 3 Cladribine 3 Asparaginase 3 tislelizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04130152 2022-10-25

PROMETEO II

SOLTI Breast Cancer Research Group

Phase EARLY_PHASE1 Completed

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡